Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Mergers and acquisitions in the pharmaceutical and biotechnology sectors set a record in 2014,...
Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a...
Valeant Pharmaceuticals faced another takeover fight Wednesday after Endo International...
Endo International is trying to lure fellow drugmaker Salix Pharmaceuticals with an offer Endo says is worth 11 percent more than the $10 billion Salix has agreed to accept from serial acquirer Valeant Pharmaceuticals.
Actavis and Allergan, Inc. announced that, at shareholder meetings held yesterday, all proposals related to Actavis’ planned acquisition of Allergan were approved by both Actavis’ and Allergan’s shareholders.
Pernix Ireland Limited has signed a definitive agreement to acquire the Zohydro ER franchise from Zogenix, Inc. The acquisition includes three extended release hydrocodone products, including an abuse-deterrent pipeline and all related intellectual property.
Concordia Healthcare Corp. has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l for $1.2 billion in cash.
In connection with the closing of the acquisition, Impax also announced that it is reshaping the operating and reporting structure of its two divisions - the Impax generic products division will now be known as "Impax Generics" and the Impax branded products division will now be known as "Impax Specialty Pharma".
Targacept and Catalyst Biosciences have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, Inc., is expected to create a financially strong company to harness the catalytic power of engineered human proteases.
Alkermes has entered into a definitive agreement to sell its manufacturing facility in Gainesville, GA, the manufacturing and royalty revenue associated with products manufactured at the facility and global rights to Meloxicam IV/IM to Recro Pharma.
Mallinckrodt and Ikaria have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis’ entire RNAi research and development portfolio and associated assets.
AbbVie and Pharmacyclics have announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies.
Baxter International and SuppreMol GmbH have announced that Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD) before working capital and other adjustments.
Patheon has reached a definitive agreement to acquire IRIX Pharmaceuticals, a company headquartered in Florence, S.C., that specializes in difficult to manufacture Active Pharmaceutical Ingredient (API) needs for drugs from early and late development, through commercial launch.
The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma.
AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.
Cardinal Health today announced plans to acquire Johnson & Johnson's Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.944 billion in cash, or approximately $1.594 billion, net of the present value of tax benefits.
Biota Pharmaceuticals has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, France. Anaconda Pharma's lead candidate is AP611074, a patented, direct-acting antiviral in development.
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies will be rebranded to reflect the new integrated management structure that has been put in place and the broader product and service offerings of the combined organizations.
Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.
Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash. The companies said Sunday that their boards of directors approved the transaction, which amounts to about $158 for each of Salix's outstanding shares.
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.
Bristol-Myers Squibb and Flexus Biosciences announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus, a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics.
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair.
Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline in an all-cash transaction valuing the company at approximately $212M.
Rite Aid and Envision Pharmaceutical Services have entered into a definitive agreement under which Rite Aid will acquire EnvisionRx, a portfolio company of leading global private investment firm TPG, in a transaction valued at approximately $2 billion, which includes the value of an expected future tax benefit of $275 million.
Actavis has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx brand acne treatment and related assets to Mayne for approximately $50M. The transaction is expected to close prior to the end of February.
- Page 1